Prospective, Randomized, Placebo-controlled, Double-blind, Multicenter, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Macitentan in Patients With Ischemic Digital Ulcers Associated With Systemic Sclerosis

Trial Profile

Prospective, Randomized, Placebo-controlled, Double-blind, Multicenter, Parallel Group Study to Assess the Efficacy, Safety and Tolerability of Macitentan in Patients With Ischemic Digital Ulcers Associated With Systemic Sclerosis

Completed
Phase of Trial: Phase III

Latest Information Update: 26 Aug 2016

At a glance

  • Drugs Macitentan (Primary)
  • Indications Skin ulcer
  • Focus Registrational; Therapeutic Use
  • Acronyms DUAL-1
  • Sponsors Actelion Pharmaceuticals
  • Most Recent Events

    • 10 May 2016 Primary endpoint of incidence rate of new digital ulcers (DUs) up to Week 16 has not been met, according to Results published in the JAMA: the Journal of the American Medical Association
    • 10 May 2016 Results of DUAL-1 and DUAL-2 studies published in the JAMA: the Journal of the American Medical Association
    • 14 Aug 2014 Planned number of patients changed to 285.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top